{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:29:40Z","timestamp":1789151380413,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200670"],"award-info":[{"award-number":["RP200670"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02232-9","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:45:01Z","timestamp":1743803101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis"],"prefix":"10.1007","volume":"27","author":[{"given":"Anthony M.","family":"Hachem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Beinart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila C.","family":"Ostos-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia Lopez","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina Diaz","family":"de Leon Derby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"2232_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng L, Wu H, Wu J, Ding Pa, He J, Sang M, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15(1):3. https:\/\/doi.org\/10.1038\/s41419-023-06389-5.","journal-title":"Cell Death Dis"},{"issue":"6382","key":"2232_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint Blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"issue":"1","key":"2232_CR3","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y.","journal-title":"Nat Commun"},{"issue":"3","key":"2232_CR4","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738.","journal-title":"Cancers"},{"issue":"6","key":"2232_CR5","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2232_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2232_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaccao.2022.06.008","volume":"4","author":"F Thuny","year":"2022","unstructured":"Thuny F, Bonaca MP, Cautela J. What is the evidence of the diagnostic criteria and screening of immune checkpoint Inhibitor\u2013Induced myocarditis?? JACC: CardioOncology. 2022;4(5):624\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2022.06.008.","journal-title":"JACC: CardioOncology"},{"issue":"6","key":"2232_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/circulationaha.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473\u201386. https:\/\/doi.org\/10.1161\/circulationaha.123.062405.","journal-title":"Circulation"},{"issue":"33","key":"2232_CR9","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"ALP Caforio","year":"2013","unstructured":"Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636\u201348. https:\/\/doi.org\/10.1093\/eurheartj\/eht210.","journal-title":"Eur Heart J"},{"issue":"5","key":"2232_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, Gradone A, Azam TU, Perry D, et al. Biomarker trends, incidence, and outcomes of immune checkpoint Inhibitor-Induced myocarditis. JACC CardioOncol. 2022;4(5):689\u2013700. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.004.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2232_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","volume":"3","author":"S Waliany","year":"2021","unstructured":"Waliany S, Neal JW, Reddy S, Wakelee H, Shah SA, Srinivas S, et al. Myocarditis surveillance with High-Sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol. 2021;3(1):137\u20139. https:\/\/doi.org\/10.1016\/j.jaccao.2021.01.004.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2232_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40959-023-00185-y","volume":"9","author":"MP O\u2019Shea","year":"2023","unstructured":"O\u2019Shea MP, Karikalan SA, Yusuf A, Barry T, Habib E, O\u2019Shea J, et al. Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis. Cardio-Oncology. 2023;9(1):34. https:\/\/doi.org\/10.1186\/s40959-023-00185-y.","journal-title":"Cardio-Oncology"},{"issue":"18","key":"2232_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/circulationaha.121.055816","volume":"144","author":"JR Power","year":"2021","unstructured":"Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation. 2021;144(18):1521\u20133. https:\/\/doi.org\/10.1161\/circulationaha.121.055816.","journal-title":"Circulation"},{"issue":"41","key":"2232_CR14","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"1","key":"2232_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/cam4.3600","volume":"10","author":"H Wang","year":"2021","unstructured":"Wang H, Zhao Y, Zhang X, Si X, Song P, Xiao Y, et al. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Med. 2021;10(1):188\u201398. https:\/\/doi.org\/10.1002\/cam4.3600.","journal-title":"Cancer Med"},{"issue":"5","key":"2232_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaccao.2022.10.007","volume":"4","author":"Y Tamura","year":"2022","unstructured":"Tamura Y, Tamura Y, Takemura R, Yamada K, Taniguchi H, Iwasawa J, et al. Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy. JACC: CardioOncology. 2022;4(5):673\u201385. https:\/\/doi.org\/10.1016\/j.jaccao.2022.10.007.","journal-title":"JACC: CardioOncology"},{"issue":"17","key":"2232_CR17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol. 2009;53(17):1475\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.007.","journal-title":"J Am Coll Cardiol"},{"issue":"9Supplement","key":"2232_CR18","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0735-1097(22)02907-2","volume":"79","author":"A Hughes","year":"2022","unstructured":"Hughes A, Power J, Orimoloye Olusola A, Nowatzke Joseph F, Tamura Y, Aras M, CLINICAL SIGNIFICANCE OF PERICARDIAL EFFUSION IN PATIENTS HOSPITALIZED WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED MYOCARDITIS, et al. JACC. 2022;79(9Supplement):1916. https:\/\/doi.org\/10.1016\/S0735-1097(22)02907-2.","journal-title":"JACC"},{"issue":"16","key":"2232_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2232_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","volume":"75","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint Inhibitor-Related myocarditis. J Am Coll Cardiol. 2020;75(5):467\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.049.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2232_CR21","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1093\/rheumatology\/keac098","volume":"61","author":"G De Luca","year":"2022","unstructured":"De Luca G, Palmisano A, Campochiaro C, Vignale D, Cavalli G, Bruno E, et al. Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. Rheumatology. 2022;61(11):4409\u201319. https:\/\/doi.org\/10.1093\/rheumatology\/keac098.","journal-title":"Rheumatology"},{"issue":"10","key":"2232_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/acm2.13365","volume":"22","author":"Z Jia","year":"2021","unstructured":"Jia Z, Wang L, Jia Y, Liu J, Zhao H, Huo L, et al. Detection of acute myocarditis using T1 and T2 mapping cardiovascular magnetic resonance: A systematic review and meta-analysis. J Appl Clin Med Phys. 2021;22(10):239\u201348. https:\/\/doi.org\/10.1002\/acm2.13365.","journal-title":"J Appl Clin Med Phys"},{"issue":"2","key":"2232_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2463\/mrms.rev.2020-0007","volume":"20","author":"Y Amano","year":"2021","unstructured":"Amano Y, Omori Y, Ando C, Yanagisawa F, Suzuki Y, Tang X, et al. Clinical importance of myocardial T(2) mapping and texture analysis. Magn Reson Med Sci. 2021;20(2):139\u201351. https:\/\/doi.org\/10.2463\/mrms.rev.2020-0007.","journal-title":"Magn Reson Med Sci"},{"issue":"1","key":"2232_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12968-022-00866-0","volume":"24","author":"AT O\u2019Brien","year":"2022","unstructured":"O\u2019Brien AT, Gil KE, Varghese J, Simonetti OP, Zareba KM. T2 mapping in myocardial disease: a comprehensive review. J Cardiovasc Magn Reson. 2022;24(1):33. https:\/\/doi.org\/10.1186\/s12968-022-00866-0.","journal-title":"J Cardiovasc Magn Reson"},{"key":"2232_CR25","doi-asserted-by":"publisher","unstructured":"Li S, Duan X, Feng G, Sirajuddin A, Yin G, Zhuang B, et al. Multiparametric cardiovascular magnetic resonance in acute myocarditis: comparison of 2009 and 2018 lake Louise criteria with endomyocardial biopsy confirmation. Front Cardiovasc Med. 2021;8. https:\/\/doi.org\/10.3389\/fcvm.2021.739892.","DOI":"10.3389\/fcvm.2021.739892"},{"issue":"3","key":"2232_CR26","doi-asserted-by":"publisher","first-page":"e190010","DOI":"10.1148\/ryct.2019190010","volume":"1","author":"JA Luetkens","year":"2019","unstructured":"Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A, et al. Comparison of original and 2018 lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort. Radiology: Cardiothorac Imaging. 2019;1(3):e190010. https:\/\/doi.org\/10.1148\/ryct.2019190010.","journal-title":"Radiology: Cardiothorac Imaging"},{"issue":"18","key":"2232_CR27","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051.","journal-title":"Eur Heart J"},{"issue":"12","key":"2232_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint Inhibitor-Associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.050.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2232_CR29","first-page":"3","volume":"1","author":"HT Aretz","year":"1987","unstructured":"Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr., et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1(1):3\u201314.","journal-title":"Am J Cardiovasc Pathol"},{"issue":"10","key":"2232_CR30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725\u201335. https:\/\/doi.org\/10.1002\/ejhf.2265.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2232_CR31","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1158\/2326-6066.Cir-24-0011","volume":"12","author":"BA Siddiqui","year":"2024","unstructured":"Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, et al. Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping Immune-Related myocarditis and myositis. Cancer Immunol Res. 2024;12(8):964\u201387. https:\/\/doi.org\/10.1158\/2326-6066.Cir-24-0011.","journal-title":"Cancer Immunol Res"},{"key":"2232_CR32","doi-asserted-by":"publisher","first-page":"107211","DOI":"10.1016\/j.carpath.2020.107211","volume":"47","author":"DV Balanescu","year":"2020","unstructured":"Balanescu DV, Donisan T, Palaskas N, Lopez-Mattei J, Kim PY, Buja LM, et al. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: pathway toward precision-based therapy. Cardiovasc Pathol. 2020;47:107211. https:\/\/doi.org\/10.1016\/j.carpath.2020.107211.","journal-title":"Cardiovasc Pathol"},{"issue":"5","key":"2232_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11886-022-01680-x","volume":"24","author":"E Ammirati","year":"2022","unstructured":"Ammirati E, Buono A, Moroni F, Gigli L, Power JR, Ciabatti M, et al. State-of-the-Art of endomyocardial biopsy on acute myocarditis and chronic inflammatory cardiomyopathy. Curr Cardiol Rep. 2022;24(5):597\u2013609. https:\/\/doi.org\/10.1007\/s11886-022-01680-x.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"2232_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1253\/circj.CJ-16-0927","volume":"81","author":"H Ishibashi-Ueda","year":"2017","unstructured":"Ishibashi-Ueda H, Matsuyama TA, Ohta-Ogo K, Ikeda Y. Significance and value of endomyocardial biopsy based on our own experience. Circ J. 2017;81(4):417\u201326. https:\/\/doi.org\/10.1253\/circj.CJ-16-0927.","journal-title":"Circ J"},{"issue":"3","key":"2232_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN guidelines insights: management of Immunotherapy-Related toxicities, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2020;18(3):230\u201341. https:\/\/doi.org\/10.6004\/jnccn.2020.0012.","journal-title":"J Natl Compr Cancer Netw J Natl Compr Canc Netw"},{"issue":"36","key":"2232_CR36","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2232_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/circulationaha.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-Oncology. Circulation. 2019;140(2):80\u201391. https:\/\/doi.org\/10.1161\/circulationaha.118.034497.","journal-title":"Circulation"},{"issue":"5","key":"2232_CR38","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2024.07.002","volume":"6","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Siddiqui BA, Deswal A. Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol. 2024;6(5):800\u20133. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.002.","journal-title":"JACC CardioOncol"},{"issue":"24","key":"2232_CR39","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/circulationaha.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor-Associated myocarditis. Circulation. 2020;141(24):2031\u20134. https:\/\/doi.org\/10.1161\/circulationaha.119.044703.","journal-title":"Circulation"},{"issue":"5","key":"2232_CR40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.Cd-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of Immune-Checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-1180.","journal-title":"Cancer Discov"},{"issue":"2","key":"2232_CR41","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/jaha.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757. https:\/\/doi.org\/10.1161\/jaha.119.013757.","journal-title":"J Am Heart Assoc"},{"key":"2232_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.gore.2018.05.014","volume":"25","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V. Myocarditis with Tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecol Oncol Rep. 2018;25:74\u20137. https:\/\/doi.org\/10.1016\/j.gore.2018.05.014.","journal-title":"Gynecol Oncol Rep"},{"issue":"10","key":"2232_CR43","first-page":"1335","volume":"33","author":"N Reddy","year":"2017","unstructured":"Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, et al. Progressive and reversible conduction disease with checkpoint inhibitors. Can J Cardiol. 2017;33(10):1335..e13-.e15.","journal-title":"Can J Cardiol"},{"issue":"7","key":"2232_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","volume":"117","author":"RY Tay","year":"2017","unstructured":"Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, et al. Successful use of equine anti-thymocyte Globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer. 2017;117(7):921\u20134. https:\/\/doi.org\/10.1038\/bjc.2017.253.","journal-title":"Br J Cancer"},{"issue":"1","key":"2232_CR45","first-page":"1","volume":"2","author":"NV Baclig","year":"2019","unstructured":"Baclig NV, Ngo C, Yeh AC, Chung SH, Cheng A, Grim J, et al. Steroid-Refractory autoimmune myocarditis after pembrolizumab therapy: failure of equine Anti-Thymocyte Globulin to prevent heart failure. J Clin Case Rep. 2019;2(1):1\u20134.","journal-title":"J Clin Case Rep"},{"issue":"9","key":"2232_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/l17-0396","volume":"167","author":"D Arangalage","year":"2017","unstructured":"Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, et al. Survival after fulminant myocarditis induced by Immune-Checkpoint inhibitors. Ann Intern Med. 2017;167(9):683\u20134. https:\/\/doi.org\/10.7326\/l17-0396.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2232_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13256-021-02934-y","volume":"15","author":"F Wang","year":"2021","unstructured":"Wang F, Liu Y, Xu W, Zhang C, Lv J, Ma S. Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature. J Med Case Rep. 2021;15(1):336. https:\/\/doi.org\/10.1186\/s13256-021-02934-y.","journal-title":"J Med Case Rep"},{"issue":"5","key":"2232_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2020.10.013","volume":"2","author":"S Liu","year":"2020","unstructured":"Liu S, Chan J, Brinc D, Gandhi S, Izenberg A, Delgado D, et al. Immune checkpoint Inhibitor-Associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression. JACC CardioOncol. 2020;2(5):800\u20134. https:\/\/doi.org\/10.1016\/j.jaccao.2020.10.013.","journal-title":"JACC CardioOncol"},{"issue":"5","key":"2232_CR49","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1002\/ehf2.13545","volume":"8","author":"AF Stein-Merlob","year":"2021","unstructured":"Stein-Merlob AF, Hsu JJ, Colton B, Berg CJ, Ferreira A, Price MM, et al. Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a Bridge to recovery. ESC Heart Fail. 2021;8(5):4301\u20136. https:\/\/doi.org\/10.1002\/ehf2.13545.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"2232_CR50","doi-asserted-by":"publisher","first-page":"e7039","DOI":"10.1002\/ccr3.7039","volume":"11","author":"P Zhong","year":"2023","unstructured":"Zhong P, Zhang C, Guan H, Yan J, He M, Zhou X. Myocarditis and myasthenia Gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report. Clin Case Rep. 2023;11(3):e7039. https:\/\/doi.org\/10.1002\/ccr3.7039.","journal-title":"Clin Case Rep"},{"key":"2232_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","volume":"135","author":"T Konstantina","year":"2019","unstructured":"Konstantina T, Konstantinos R, Anastasios K, Anastasia M, Eleni L, Ioannis S, et al. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Lung Cancer. 2019;135:29\u201332. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.015.","journal-title":"Lung Cancer"},{"issue":"1","key":"2232_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12871-023-02257-z","volume":"23","author":"JA Cuenca","year":"2023","unstructured":"Cuenca JA, Hanmandlu A, Wegner R, Botdorf J, Tummala S, Iliescu CA, et al. Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature. BMC Anesthesiol. 2023;23(1):310. https:\/\/doi.org\/10.1186\/s12871-023-02257-z.","journal-title":"BMC Anesthesiol"},{"issue":"1","key":"2232_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-021-00095-x","volume":"7","author":"RS Zhang","year":"2021","unstructured":"Zhang RS, Padegimas A, Murphy KM, Evans PT, Peters CJ, Domenico CM, et al. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series. Cardiooncology. 2021;7(1):13. https:\/\/doi.org\/10.1186\/s40959-021-00095-x.","journal-title":"Cardiooncology"},{"key":"2232_CR54","doi-asserted-by":"publisher","unstructured":"Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001887.","DOI":"10.1136\/jitc-2020-001887"},{"issue":"3","key":"2232_CR55","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.jtho.2019.09.080","volume":"15","author":"H Wang","year":"2020","unstructured":"Wang H, Tian R, Gao P, Wang Q, Zhang L. Tocilizumab for fulminant programmed death 1 Inhibitor-Associated myocarditis. J Thorac Oncol. 2020;15(3):e31\u20132. https:\/\/doi.org\/10.1016\/j.jtho.2019.09.080.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2232_CR56","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol. 2020;31(9):1273\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.005.","journal-title":"Ann Oncol"},{"issue":"24","key":"2232_CR57","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint Inhibitor-Associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139. https:\/\/doi.org\/10.1056\/NEJMc1901677.","journal-title":"N Engl J Med"},{"issue":"3","key":"2232_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.Cd-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, et al. A genetic mouse model recapitulates immune checkpoint Inhibitor-Associated myocarditis and supports a Mechanism-Based therapeutic intervention. Cancer Discov. 2021;11(3):614\u201325. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0856.","journal-title":"Cancer Discov"},{"key":"2232_CR59","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","volume":"385","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Ali H-J, Koutroumpakis E, Ganatra S, Deswal A. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024;385:e075859. https:\/\/doi.org\/10.1136\/bmj-2023-075859.","journal-title":"BMJ"},{"issue":"2","key":"2232_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","volume":"118","author":"JE Salem","year":"2025","unstructured":"Salem JE, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al. Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118(2):106\u201315. https:\/\/doi.org\/10.1016\/j.acvd.2024.12.005.","journal-title":"Arch Cardiovasc Dis"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02232-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:56:21Z","timestamp":1772096181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02232-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02232-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"25 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Palaskas is supported by the Cancer Prevention & Research Institute of Texas (CPRIT) RP200670, NIH\/NCI 1P01CA261669-01, and Kiniksa Pharmaceuticals. The remaining authors have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"N.P. is a consultant for Kiniksa Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"78"}}